M
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ: MLTX (MoonLake Immunotherapeutics)
Kemas kini terakhir: 3 jam lalu17.96
-1.45 (-7.47%)
| Penutupan Terdahulu | 19.41 |
| Buka | 19.50 |
| Jumlah Dagangan | 1,228,888 |
| Purata Dagangan (3B) | 1,390,901 |
| Modal Pasaran | 1,288,232,576 |
| Harga / Buku (P/B) | 3.83 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| EPS Cair (TTM) | -2.30 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 21.11 |
| Aliran Tunai Operasi (OCF TTM) | -139.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.40 M |
| Pulangan Atas Aset (ROA TTM) | -19.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | MoonLake Immunotherapeutics | Menaik | Menurun |
AISkor Stockmoo
0.8
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.80 |
|
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 15.34% |
| % Dimiliki oleh Institusi | 96.70% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (Clear Street, 289.76%) | Beli |
| Median | 30.00 (67.04%) | |
| Rendah | 10.00 (Goldman Sachs, -44.32%) | Jual |
| Purata | 31.86 (77.39%) | |
| Jumlah | 5 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 17.73 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Clear Street | 11 Mar 2026 | 70.00 (289.76%) | Beli | 17.84 |
| HC Wainwright & Co. | 02 Mar 2026 | 40.00 (122.72%) | Beli | 17.68 |
| 03 Feb 2026 | 32.00 (78.17%) | Beli | 15.37 | |
| RBC Capital | 02 Mar 2026 | 13.00 (-27.62%) | Pegang | 17.68 |
| 20 Feb 2026 | 12.00 (-33.18%) | Pegang | 18.77 | |
| Needham | 26 Feb 2026 | 25.00 (39.20%) | Beli | 17.68 |
| 23 Feb 2026 | 25.00 (39.20%) | Beli | 18.68 | |
| Oppenheimer | 24 Feb 2026 | 35.00 (94.88%) | Beli | 18.20 |
| BTIG | 23 Feb 2026 | 30.00 (67.04%) | Beli | 18.68 |
| 09 Feb 2026 | 24.00 (33.63%) | Beli | 15.75 | |
| Goldman Sachs | 15 Jan 2026 | 10.00 (-44.32%) | Jual | 16.35 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | - | 18.64 | -3,750,000 | -69,900,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,750,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -69,900,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 18.64 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | Pengarah | 31 Mar 2026 | Jual (-) | 3,750,000 | 18.64 | 69,900,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |